EU and US could reach trade deal this weekend - Reuters
On Thursday, H.C. Wainwright analyst Joseph Pantginis adjusted the price target for BiomX (NYSE:PHGE) shares, reducing it to $15.00 from the previous $21.00, while reiterating a Buy rating on the stock. This decision followed BiomX’s recent announcement of its first-quarter financial results for the year 2025. Currently trading at $0.56, the stock has seen a significant decline of 83% over the past year, though InvestingPro analysis suggests the stock is currently undervalued.
The company reported a loss per share (EPS) of $0.33, which was more favorable than the analyst’s estimate of a $0.42 loss per share. BiomX concluded the quarter with $21.2 million in cash reserves, which is anticipated to fund operations into the first quarter of 2026. InvestingPro data shows the company maintains a healthy current ratio of 3.35, with liquid assets exceeding short-term obligations, though it’s quickly burning through cash. Get access to 10+ additional ProTips and comprehensive financial analysis with InvestingPro.
BiomX shared a series of anticipated milestones, including ongoing discussions with the U.S. Defense Health Agency regarding their BX211 program for diabetic foot osteomyelitis, after reporting positive Phase 2 results. The company is awaiting FDA feedback and plans to commence a Phase 2/3 trial. Additionally, BiomX anticipates a Phase 2b study data readout for BX004, aimed at treating cystic fibrosis, in the first quarter of 2026.
In the second half of 2025, BiomX has scheduled meetings with the FDA and other regulatory bodies to discuss real-world evidence data in cystic fibrosis patients. This data explores the connection between the reduction of P. aeruginosa and clinical outcomes. The company aims to gain regulatory support for potential future filings.
Pantginis reiterated the Buy rating despite the reduced price target, attributing the adjustment to an increase in the company’s share count.
In other recent news, BiomX has reported significant developments surrounding its Phase 2 trial of BX211 for diabetic foot osteomyelitis (DFO) associated with S. aureus. The trial results showed a statistically significant reduction in ulcer size and depth, with noticeable improvements starting at week 7 and continuing through week 13. These promising results have led H.C. Wainwright to raise the price target for BiomX to $21, maintaining their Buy rating. The analysts’ decision reflects confidence in the potential of BX211 as a treatment option for DFO, especially given the lack of new drug approvals for diabetic foot infections in the past two decades. Additionally, BiomX raised $12 million to further fund its studies, including those for cystic fibrosis. The company is exploring regulatory pathways and considering a potential Phase 3 trial, which could solidify its position in the biotechnology field. Despite the positive trial outcomes, investor caution was evident as BiomX’s stock experienced a decline in aftermarket trading. BiomX plans to present additional data at upcoming scientific conferences and is actively engaging with regulatory bodies to discuss the future of BX211.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.